Merck & Co., Inc.
NYSE: MRK
Stalled Progress in the Fight Against HIV?
Another HIV vaccine bites the dust. Has progress in the fight against HIV stalled?Why Immunotherapy Stocks Could Be Set for a Big Move
The American Society of Clinical Oncology's annual meeting kicks off late next week, and this group of stocks looks primed to impress analysts and investors alike.Merck Halts Parkinson's Drug Trials
The health care giant doesn’t obtain the desired results, opts to discontinue preladenant drug trials.Unclear Future for Merck's Insomnia Drug
The FDA advisory committee has discussed Suvorexant; now shareholders need to get ready for the agency's final decision this summer.Merck Stock Is a Good Investment (According to Merck)
Merck accelerates its buyback.